Sector News

India’s Dr Reddy’s to buy some UCB brands for $128 mln

April 2, 2015
Life sciences
(Reuters) – India’s second-largest drugmaker by sales, Dr Reddy’s Laboratories Ltd, will buy some established brands of Belgian drugmaker UCB SA in South Asia for 8 billion rupees ($128.38 million), the company said on Wednesday.
 
As competition heats up, Indian drugmakers are looking to strengthen existing porfolios in fast-growing emerging markets, as well as at home.
 
The country’s largest drugmaker, Sun Pharmaceutical Industries Ltd, closed a deal to buy rival Ranbaxy Laboratories Ltd last month, strengthening its presence, particularly in emerging markets.
 
Dr Reddy’s said the acquisition of brands in India, Nepal, Sri Lanka and the Maldives, would help it win a bigger foothold in the areas of respiratory, dermatology and pediatrics drugs.
 
The acquired business generated revenue of about 1.5 billion rupees in 2014, Dr Reddy’s said.
 
The India part of the business employs about 350 people.
 
Some brokerege analysts, however, expressed concern about the acquisition cost, with the deal valuing the UCB business more than five times its sales, which, they said, was higher than the industry standard.
 
“You would demand this kind of valuation when you’re buying the leader in the industry. And I’m not sure if Dr Reddy’s has got leading brands from UCB,” said Nimish Mehta of Equirus Securities.
 
UCB Chief Operating Officer Mark McDade said in a statement the deal would allow the Belgian company to sharpen its focus on its neurology portfolio in India. Dr Reddy’s said it expected to close the deal in the first quarter of this financial year.
 
Last month, Reuters reported that Dr Reddy’s was in talks with UCB for a deal concerning the latter’s Indian operations, citing a source with direct knowledge of the matter. ($1=62.3150 Indian rupees) (Reporting by Zeba Siddiqui in Mumbai; Editing by Clarence Fernandez; Editing by Sumeet Chatterjee and Clarence Fernandez)

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.